Celgene’s roving band of dealmakers has selected San Diego-based Abide Therapeutics for its latest option package, taking an equity stake in the biotech as it settles into a front row seat on its progress regarding a broad R&D front and gaining first dibs on Abide’s lead program.

…read more

Source: Celgene gambles $50M on Abide and its R&D work on enzyme ‘superfamily’


0 No comments